The Role of Sodium Bicarbonate as Adjuvant Treatment of Computed Tomography Identified COVID-19 Pneumonia

Mansoura University

Status: Unknown

Conditions: Covid19; Pneumonia

Treatments: Drug: Sodium Bicarbonate

Study type: Interventional

Funder types: Other

Identifiers

NCT04374591

Sodium Bicarbonate COVID-19

Details and patient eligibility

About

To report the possible role of S.B 8.4% in the treatment of COVID-19pneumonia.

Enrollment: 180 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age >18 years.
• Fever ≥ 38º C with upper respiratory tract manifestations, generalized bone ache with or without gastrointestinal symptoms as diarrhea.
• Chest CT with signs suggestive of COVID-19.
• Mild and moderate cases of COVID-19 pneumonia with respiratory and hemodynamic stability. - High C reactive protein (CRP).- With or without history of contact with index case who is isolated in a governmental hospital assigned for treatment of patients proved to have RT-PCR positive test for COVID-19
• With or without abnormalities in the total or differential white cell count.
• Welling to sign a fully informed consent.

Exclusion criteria

• Severe and critical illness with respiratory failure and/ or hemodynamic instability.
• CT with pleural effusion with or without lung cavitation.
• Other organ failure.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

180 participants in 2 patient groups, including a placebo group

Sodium Bicarbonate

Other group

Description:

Inhalation of Sodium Bicarbonate 8.4% via nebulizer

Treatment:

Drug: Sodium Bicarbonate

Control

Placebo Comparator group

Description:

placebo

Treatment:

Drug: Sodium Bicarbonate